Other · developed by BioNTech
BNT168 is an investigational agent given by intramuscular injection in the deltoid muscle. It is studied in HIV-1 infection, which causes acquired immunodeficiency syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07698600 | Phase 1 | HIV -1 Infection | Recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HIV -1 Infection
Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →